Efficacy of Black seed (Nigella sativa) in the management of Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Nutritional, Metabolic, Endocrine
- Registration Number
- PACTR202310875852492
- Lead Sponsor
- African ai Japan project JICA JKUAT PAUSTI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
All participants with Type 2 diabetes attending care at Gatundu Level 5 Hospital Non-communicable Disease Center who consented to participate and signed a written informed consent.
Exclusion Criteria
Type 2 diabetes patient attending care at Gatundu Level 5 Hospital Non-communicable Disease Center WHO HAD COMPLICATION SUCH AS RENAL FAILURE, STROKE.
Those who did not consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of thymoquinone in Nigella sativa improve insulin sensitivity in Type 2 Diabetes?
How does Nigella sativa compare to metformin in glycemic control for Type 2 Diabetes patients?
Which biomarkers (e.g., PPARγ, SIRT1) predict response to Nigella sativa in metabolic syndrome populations?
What adverse events are associated with Nigella sativa supplementation in T2D clinical trials?
Are there synergistic effects of combining Nigella sativa with GLP-1 agonists or SGLT2 inhibitors in diabetes management?